We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$270M
AUM Growth
-$44.3M
Cap. Flow
-$68M
Cap. Flow %
-25.15%
Top 10 Hldgs %
74.66%
Holding
64
New
15
Increased
6
Reduced
6
Closed
18

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$10.4M
2
STAA icon
STAAR Surgical
STAA
+$9.86M
3
ICLR icon
Icon
ICLR
+$6.74M
4
NVAX icon
Novavax
NVAX
+$6M
5
HSKA
Heska Corp
HSKA
+$5.68M

Top Sells

Rank Stock Value
1
COR icon
Cencora
COR
+$31.3M
2
GSK icon
GSK
GSK
+$23.3M
3
SNY icon
Sanofi
SNY
+$13.6M
4
CNC icon
Centene
CNC
+$9.88M
5
SKIN icon
SkinHealth Systems
SKIN
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 59.82%
2 Financials 8.65%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLNN icon
51
PUT
Clene
CLNN
$68.7M
– –
-1,135
Closed -$64K
CNC icon
52
Centene
CNC
$33.1B
– –
-127,011
Closed -$9.88M
GSK icon
53
GSK
GSK
$103B
– –
-790,600
Closed -$23.3M
HUMAW icon
54
Humacyte Inc Warrant
HUMAW
$1.09M
– –
-49,998
Closed -$58K
SKIN icon
55
SkinHealth Systems
SKIN
$91.4M
– –
-658,964
Closed -$7.77M
SNN icon
56
Smith & Nephew
SNN
$12.7B
– –
-228,390
Closed -$5.3M
SNY icon
57
Sanofi
SNY
$103B
– –
-356,888
Closed -$13.6M
UHS icon
58
Universal Health Services
UHS
$10.4B
– –
-40,725
Closed -$3.59M
NARI
59
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-57,466
Closed -$4.17M
NBSE
60
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-12,972
Closed -$102K
PNT
61
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-544,545
Closed -$4.21M
RCOR.WS
62
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
– –
-400,000
Closed -$37K
RCOR
63
DELISTED
Renovacor, Inc.
RCOR
– –
-735,908
Closed -$1.85M
CMAXW
64
DELISTED
CareMax, Inc. Warrant
CMAXW
– –
-12,808
Closed -$23K
1 2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Sio Capital Management held 64 positions worth $270M, down 14% from $315M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Sio Capital Management withdrew a net $68M in Q4 2022, closing 18 positions and reducing 6 holdings. Its most notable exit was GSK, an estimated $23.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 64% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sio Capital Management opened a new position in Medtronic worth $9.95M.

  • Sio Capital Management's largest Q4 2022 buy was Medtronic: 128,000 shares worth $9.95M.
  • Sio Capital Management added most to United Therapeutics in Q4 2022, an estimated $2.52M increase.
  • Sio Capital Management's biggest Q4 2022 reduction was Cencora, cutting an estimated $31.3M.
  • Sio Capital Management fully exited GSK in Q4 2022, selling an estimated $23.3M.
  • Sio Capital Management's ten largest holdings make up 75% of its $270M portfolio in Q4 2022.
  • Sio Capital Management opened 15 new positions and closed 18 in Q4 2022.
  • Sio Capital Management's portfolio value fell 14% quarter-over-quarter to $270M.

Based on Sio Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.